FBXO32 and Atrophy: Subsequently, activated AMPK can phosphorylate six regulatory sites on FOXO3, promoting its nuclear retention and activation [47, 48], leading to the upregulation of key atrophy genes Atrogin-1 and MuRF1, resulting in muscle atrophy.